A PHASE 2-3, MULTICENTER, RANDOMIZED, DOUBLE BLIND STUDY OF SELINEXOR (KPT-330) VERSUS PLACEBO IN PATIENTS WITH ADVANCED
UNRESECTABLE DEDIFFERENTIATED LIPOSARCOMA (DDLS)
The purpose of this study is to study the effects, good and bad, of the study drug KPT-330 versus placebo on participants and their advanced unresectable dedifferentiated liposarcoma.
advanced unresectable dedifferentiated liposarcoma
≥12 years old who have failed at least one prior treatment for their cancer. Further labs, scans, and review of medical history will be done to confirm eligibility.
12 - 120
Healthy Volunteers Needed
Duration of Participation
For as long as the participant is seeing benefit from the study drug
Knight Cancer Institute Clinical Trials
Karyopharm Therapeutics Inc